APRI (Aprinoia Therapeutics) Forward PE Ratio: 0.00 (As of Jul. 04, 2026)


What is Aprinoia Therapeutics Forward PE Ratio?

Aprinoia Therapeutics APRI Forward PE Ratio is 0.00 as of Jul. 04, 2026.

Aprinoia Therapeutics's Forward PE Ratio for today is 0.00.

Aprinoia Therapeutics's PE Ratio without NRI for today is 0.00.

Aprinoia Therapeutics's PE Ratio (TTM) for today is 0.00.

Aprinoia Therapeutics  (NAS:APRI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Aprinoia Therapeutics Forward PE Ratio Related Terms

Aprinoia Therapeutics Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Forward PE Ratio Chart

Aprinoia Therapeutics Annual Data
Trend
Forward PE Ratio

Aprinoia Therapeutics Semi-Annual Data
Forward PE Ratio

APRI vs : Forward PE Ratio Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Forward PE Ratio falls into.


Aprinoia Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Aprinoia Therapeutics (APRI) has a Forward PE Ratio of 0.00 as of Jul. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Forward PE Ratio too high?
Aprinoia Therapeutics' current Forward PE Ratio is 0.00.
How does Aprinoia Therapeutics' Forward PE Ratio compare to ?
Aprinoia Therapeutics' Forward PE Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Forward PE Ratio is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.